Stevanato Group (STVN) investor relations material

Customer relationships and market positioning

• Maintains long-term partnerships with customers, supported by high switching costs and integration into regulatory filings.

• Leverages over 70 years of history and unique value propositions to drive double-digit organic growth and global leadership.

• Positioned as an ideal partner for the pharmaceutical industry, with a focus on high-value solutions and customer proximity.

Growth drivers and product trends

• High-value solutions, especially Nexa syringes and sterile cartridges, are driving strong revenue growth, with GLP-1s representing 21–22% of total revenue.

• Biologics and GLP-1s are key secular tailwinds, with self-administration trends boosting demand for advanced drug delivery systems.

• Conversion from bulk to sterile cartridges is accelerating, prompting capacity shifts to meet demand.

Capacity expansion and operational flexibility

• Significant investments in Fishers (Indiana) and Latina (Italy) plants are increasing capacity for high-value products, with most CapEx already deployed.

• Latina plant is no longer dilutive and is expected to further increase high-value product output; Fishers is on track for full ramp-up by H2 2028.

• Demonstrated ability to quickly convert production lines (e.g., vials to cartridges) in response to market needs, with a typical conversion time of 9–10 months.